Acid-based Parameters on PH-impedance Testing Predict Symptom Improvement with Medical Management Better Than Impedance Parameters
Overview
Affiliations
Objectives: pH-impedance testing detects reflux events irrespective of pH, but its value in predicting treatment outcome is unclear. We prospectively evaluated subjects treated medically after pH-impedance testing to determine predictors of symptom improvement.
Methods: Subjects referred for pH-impedance testing completed questionnaires in which dominant symptoms and global symptom severity (GSS) were recorded. Acid-reflux parameters (acid-exposure time, AET; symptom association by Ghillebert probability estimate, GPE; symptom index, SI) and impedance reflux parameters (reflux-exposure time, RET; number of reflux events; GPE and SI with impedance data) were extracted. Symptoms and GSS were prospectively reevaluated after medical therapy. Univariate and multivariate analyses determined predictors of GSS improvement following medical management.
Results: Over 5 years, 128 subjects (mean 53.3±1.3 years, 66.4% female; typical symptoms 57.0%, 53.9% tested on therapy) underwent pH-impedance testing and subsequent medical therapy for reflux symptoms, and completed required questionnaires. On follow-up 3.35±0.14 years later, mean GSS declined by 45.0%, with 42.2% patients reporting ≥50% GSS improvement. On univariate analysis, total AET, AET≥4.0%, and GPE for all reflux events predicted both linear and ≥50% GSS improvement, but RET and number of reflux events did not. On multivariate analysis, controlling for testing on or off therapy, only AET (P=0.003) and GPE for all reflux events (P=0.029) predicted GSS improvement.
Conclusions: Acid-based reflux parameters offer greater value over impedance-based nonacid-reflux parameters in predicting symptomatic responses to proton pump inhibitor (PPI) therapy. Our findings support conducting pH-impedance studies off PPI therapy to maximize clinical utility in predicting outcome.
Latin American consensus on diagnosis of gastroesophageal reflux disease.
Olmos J, Pandolfino J, Piskorz M, Zamora N, Valdovinos Diaz M, Remes Troche J Neurogastroenterol Motil. 2024; 36(3):e14735.
PMID: 38225792 PMC: 11720354. DOI: 10.1111/nmo.14735.
Voulgaris T, Lekakis V, Orfanidou A, Vlachogiannakos J, Kamberoglou D, Papatheodoridis G J Clin Med. 2022; 11(18).
PMID: 36143030 PMC: 9503370. DOI: 10.3390/jcm11185383.
Visaggi P, Mariani L, Baiano Svizzero F, Tarducci L, Sostilio A, Frazzoni M Esophagus. 2022; 19(4):525-534.
PMID: 35768671 PMC: 9436885. DOI: 10.1007/s10388-022-00933-6.
Ota K, Takeuchi T, Kojima Y, Sugawara N, Nishida S, Iwatsubo T BMC Gastroenterol. 2021; 21(1):432.
PMID: 34794376 PMC: 8603480. DOI: 10.1186/s12876-021-02022-x.
Zhu Y, Tang J, Shi W, Wang S, Wu M, Lu L Ther Adv Chronic Dis. 2021; 12:20406223211056719.
PMID: 34777741 PMC: 8586183. DOI: 10.1177/20406223211056719.